{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:34:25Z","timestamp":1793093665967,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R35GM122559"],"award-info":[{"award-number":["5R35GM122559"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.bmcl.2021.128484","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T18:07:25Z","timestamp":1638295645000},"page":"128484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics"],"prefix":"10.1016","volume":"57","author":[{"given":"James","family":"Peek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bimal","family":"Koirala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean F.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bmcl.2021.128484_b0005","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a021147","article-title":"Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm","volume":"5","author":"Chakraborty","year":"2015","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"10.1016\/j.bmcl.2021.128484_b0010","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128484_b0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber Lung Dis"},{"issue":"7","key":"10.1016\/j.bmcl.2021.128484_b0020","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128484_b0025","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00077-17","article-title":"Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?","volume":"31","author":"Domalaon","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"7","key":"10.1016\/j.bmcl.2021.128484_b0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1039\/C7NP00006E","article-title":"Bifunctional antimicrobial conjugates and hybrid antimicrobials","volume":"34","author":"Klahn","year":"2017","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.bmcl.2021.128484_b0035","unstructured":"Ding CZ, Ma Z, Li J, Harran S, He Y, Minor KP, et al. (R\/S) rifamycin derivatives, their preparations and pharmaceutical compositions. U.S. Patent 7,226,931, 2007."},{"key":"10.1016\/j.bmcl.2021.128484_b0040","unstructured":"Ding CZ, Kim IH, Wang J, Ma Z, Jin Y, Combrink KD, et al. Nitroheteroaryl-containing rifamycin derivatives. US Patent 7,678,791, 2010."},{"key":"10.1016\/j.bmcl.2021.128484_b0045","unstructured":"Li J, Ding CZ, Ma Z. Rifamycin C-11 oxime derivatives effective against drug-resistant microbes. U.S. Patent 7,265,107, 2007."},{"key":"10.1016\/j.bmcl.2021.128484_b0050","unstructured":"Ding CZ, Jin Y, Combrink KD, Kim IH. Quinolone carboxylic acid-substituted rifamycin derivatives. U.S. Patent 7,884,099, 2011."},{"key":"10.1016\/j.bmcl.2021.128484_b0055","unstructured":"Ma Z, Jin Y, Li J, Ding CZ, Minor KP, Longgood JC, et al. Rifamycin derivatives effective against drug-resistant microbes. U.S. Patent 7,247,634, 2007."},{"issue":"14","key":"10.1016\/j.bmcl.2021.128484_b0060","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1021\/acs.jmedchem.6b00485","article-title":"Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections","volume":"59","author":"Ma","year":"2016","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2021.128484_b0065","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1128\/AAC.01649-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.bmcl.2021.128484_b0070","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1128\/AAC.01651-07","article-title":"In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci","volume":"52","author":"Robertson","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128484_b0075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7164\/antibiotics.41.264","article-title":"Isolation and structure of a new ansamycin antibiotic kanglemycin A from a Nocardia","volume":"41","author":"Wang","year":"1988","journal-title":"J Antibiot (Tokyo)"},{"issue":"2","key":"10.1016\/j.bmcl.2021.128484_b0080","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.molcel.2018.08.028","article-title":"Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis","volume":"72","author":"Mosaei","year":"2018","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.bmcl.2021.128484_b0085","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1038\/s41467-018-06587-2","article-title":"Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism","volume":"9","author":"Peek","year":"2018","journal-title":"Nat Commun"},{"issue":"Suppl 2","key":"10.1016\/j.bmcl.2021.128484_b0090","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.survophthal.2004.01.005","article-title":"Fluoroquinolones: mechanism of action, classification, and development of resistance","volume":"49","author":"Blondeau","year":"2004","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"10.1016\/j.bmcl.2021.128484_b0095","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1021\/acsinfecdis.0c00223","article-title":"A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens","volume":"6","author":"Peek","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"12","key":"10.1016\/j.bmcl.2021.128484_b0100","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/chem.201705392","article-title":"Highly Efficient Synthesis of a Staphylococcus aureus Targeting Payload to Enable the First Antibody-Antibiotic Conjugate","volume":"24","author":"Linghu","year":"2018","journal-title":"Chemistry"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21007113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X21007113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:42:55Z","timestamp":1760773375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X21007113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":20,"alternative-id":["S0960894X21007113"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128484","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2021.128484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128484"}}